Eli Lilly Leaps Past Regeneron's COVID-19 Treatment Candidate
New coronavirus treatments are racing along the development timeline so quickly that it's hard to tell who's in the lead from one moment to the next. Until recently, Regeneron Pharmaceuticals (NASDAQ: REGN) appeared to be furthest ahead with a new COVID-19 treatment, but Eli Lilly (NYSE: LLY) and the big pharmaceutical company's new collaboration partner, AbCellera, have already beaten Regeneron to an important milestone.
Eli Lilly recently began dosing patients with LY-CoV555, an experimental antibody that was isolated from one of the first U.S. patients to recover from COVID-19. Regeneron's been progressing at top speed with a similar program called REGN-COV2, but patients aren't expected to begin taking it until later this month.
Image source: Getty Images.
Source Fool.com
